London & the life sciences
Written By
Partner
UK
I'm co-head of our London corporate team where I have over 20 years' experience advising clients on corporate transactions, including mergers and acquisitions (and disposals), equity capital markets transactions, private equity and venture capital investments/exits, joint ventures and corporate reorganisations.
Partner
UK
As one of our firm's most experienced intellectual property partners, specialising in transactional IP matters, I offer a wealth of knowledge to businesses at the cutting edge of research, development and technology, in a variety of sectors for which IP is of prime importance.
Europe’s biotech industry is more buoyant now than it’s ever been.
A combination of eager investors, the high-speed development of COVID-19 vaccines, exciting scientific developments and last year’s acceleration of existing trends is driving the sector to new heights. And as part of one of the world’s largest life science technology clusters in the so-called Golden Triangle with Oxford and Cambridge, London is riding that wave.
Latest insights
More Insights
Pantech v Google: Tokyo District Court grants first injunction for SEP infringement
3 minutes Sep 08 2025
EU Revised Product Liability Directive 2024: Navigating the New Liability Framework for Non-EU Manufacturers
6 minutes Sep 04 2025
UPC Litigation Risks for Chinese Firms: Service Delays Could Mean Surprise Judgments
3 minutes Sep 01 2025